HUP0000271A2 - Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery - Google Patents
Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgeryInfo
- Publication number
- HUP0000271A2 HUP0000271A2 HU0000271A HUP0000271A HUP0000271A2 HU P0000271 A2 HUP0000271 A2 HU P0000271A2 HU 0000271 A HU0000271 A HU 0000271A HU P0000271 A HUP0000271 A HU P0000271A HU P0000271 A2 HUP0000271 A2 HU P0000271A2
- Authority
- HU
- Hungary
- Prior art keywords
- glp
- catabolic changes
- peptide
- glucagon
- abolish
- Prior art date
Links
- 230000001925 catabolic effect Effects 0.000 title abstract 4
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 title abstract 2
- 238000001356 surgical procedure Methods 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 8
- 206010022489 Insulin Resistance Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- 230000003054 hormonal effect Effects 0.000 abstract 2
- 230000002473 insulinotropic effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Method (A) for attenuating post-surgical catabolic changes and insulin resistance, comprises administering glucagon-like peptide-1 (GLP-1), a GLP-1 analogue, a GLP-1 derivative, or a salt of this compound. Also claimed are: (1) a method (B) for attenuating post-surgical catabolic changes and hormonal responses to stress, comprising administering a compound which exerts insulino-tropic activity by interacting with the same receptor (or receptors) with which GLP-1, GLP-1 analogues and GLP-1 derivatives interact in exerting their insulino-tropic activity, and (2) a method (C) for attenuating post-surgical catabolic changes and hormonal responses to stress, comprising administering a compound which enhances insulin sensitivity by interacting with the same receptor (or receptors) with which GLP-1, GLP-1 analogues and GLP-1 derivatives interact to enhance insulin sensitivity.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/916,991 US6006753A (en) | 1996-08-30 | 1997-08-21 | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0000271A2 true HUP0000271A2 (en) | 2000-07-28 |
| HUP0000271A3 HUP0000271A3 (en) | 2000-10-30 |
Family
ID=25438198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000271A HUP0000271A3 (en) | 1997-08-21 | 1997-08-26 | Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery |
Country Status (1)
| Country | Link |
|---|---|
| HU (1) | HUP0000271A3 (en) |
-
1997
- 1997-08-26 HU HU0000271A patent/HUP0000271A3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0000271A3 (en) | 2000-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4092697A (en) | Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery | |
| ATE193541T1 (en) | INSULINOTROPIC HORMONE | |
| PL331922A1 (en) | Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor | |
| WO1999043705A8 (en) | N-terminally truncated glp-1 derivatives | |
| BG105079A (en) | Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance | |
| PT946191E (en) | USE OF GLP-1 ANALOGUES AND DERIVATIVES ADMINISTERED UNDERLYING IN THE ADJUSTMENT OF OBESITY | |
| WO2001009138A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
| EP1695983A3 (en) | Glucagon-like peptide-1 analogs | |
| CO5090908A1 (en) | PROCEDURE FOR MANAGING INSULINOTROPIC PEPTIDES | |
| ATE156492T1 (en) | BOMB ANALOGUES | |
| GR3032307T3 (en) | Site-directed mutagenesis modified glycoprotein hormones and methods of use. | |
| AU7284098A (en) | Method for preventing gastritis using amylin or amylin agonists | |
| ES2174838T3 (en) | METHOD TO INCREASE THE INTESTINE ABSORPTION. | |
| BG104059A (en) | Diabetes treatment with rosiglytazone and insulin | |
| WO1999021540B1 (en) | Method of reducing craving in mammals | |
| WO1990013643A3 (en) | Glycoprotein hormone receptor molecules | |
| HUP0000271A2 (en) | Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery | |
| WO2003045942A3 (en) | Chemokine receptor antagonists and methods of use thereof | |
| AU8019898A (en) | Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome | |
| MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
| DK1058544T3 (en) | Inhibition of TNF activity by preparations comprising heparin and soluble TNF receptors | |
| BR9915214A (en) | Combinations containing a beta-agonist and an additional anti-diabetic agent | |
| WO2001009119A3 (en) | Chemokine receptor antagonists | |
| MY103498A (en) | Dl-5-[(2-benzyl-3, 4-dihydro-2h-benzopyran-6-yl)methyl] thiazolidine-2, 4-dione as an anti-atherosclerosis agent | |
| EP0293160A3 (en) | Parathyroid hormone antagonists with enhanced metabolic properties |